RBC Capital Reiterates Outperform Rating on Definium Therapeutics Inc (DFTX), sees favorable set up
Tweet Send to a Friend
RBC Capital analyst Brian Ambrahams reiterated an Outperform rating and $36.00 price target on Definium Therapeutics Inc (NASDAQ: DFTX).The analyst ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
